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Nothinzgtendsso much to theadvancementofknowledge
as theapplication ofa new instrument.
Sir Humphrey Davy
Why Not Use It All?
One ofthe prominent features ofthe recent Annual Meeting ofthe
Society ofToxicology (SOT) in New Orleans, Louisiana, was the
debate on a hypothetical motion to have the results ofmechanistic
toxicity studies supersede ambiguous epidemiological data in
chemical risk assessments for humans. The audience was polled
prior to the debate, but the results have little to say about the mer-
its ofthe question. The motion itself is flawed, as either a vote for
or against could well prevent the assumed underlying goal of
strengthening the science base on which public health policy deci-
sions are made. The motion implies that one should choose either
weak epidemiology data or mechanistic information. However,
both mechanistic data and epidemiological findings are often sug-
gestive, but not conclusive, when taken alone. With this in mind, it
seems imprudent to discard one set ofinconclusive data for another
set ofinconclusive data.
Instead, scientists and policy makers should attempt to inte-
grate all of the available data into health risk assessments.
Integration ofdiverse data sets arising from human studies, animal
toxicological studies, and mechanistic studies requires input from
multiple scientific disciplines. Most importantly, it requires
reliance on sound scientific judgment. Though difficult, this
approach maximizes the use of all relevant information in public
health decisions, and ifproperly organized and not overly prescrip-
tive, can provide a template for describing uncertainty and research
approaches that could reduce this uncertainty.
The timing of the SOT motion is somewhat puzzling, consid-
ering that many public health agencies and institutions are already
moving away from sole reliance on single data sets or exclusive
guidelines for decision making. The examples are numerous and
include the U.S. Environmental Protection Agency (EPA), the
International Agency for Research on Cancer (IARC), the U.S.
Food and Drug Administration (FDA), and the National
Toxicology Program (NTP). In the case ofthe EPA, the proposed
revised guidelines for cancer and noncancer risk assessments explic-
itly require a "weight ofevidence" approach in risk assessments (1).
Currently, the draft revised guidelines are being applied to risk
assessments for dioxin, chloroform, butadiene, and others. Lessons
learned from these applications will be instructive in improving the
process by which the guidelines are applied. For example, the
EPA's mandate to evaluate which risk assessment circumstances for
children will require the use of additional uncertainty factors will
benefit from new methods for integrating data from human, toxi-
cology, and mechanistic studies by providing a more rational basis
on which to decide whether to apply such factors and, ifso, what
the magnitude of such factors should be. Bill Farland, director of
the EPA's National Center for Environmental Assessment, has
been a strong advocate for implementation ofthe proposed revised
guidelines. In contrast, exclusion ofrelevant data, because it is not
conclusive by itself, would diminish the EPA's effort to make deci-
sions on a scientific basis.
In 1992, IACRC revised its guidelines for classification ofcarcino-
gens (2). The new guidelines, like the EPA's proposed risk assess-
ment guidelines, call for the use of mechanistic data along with
human epidemiological and animal cancer data by the working
groups that determine whether an agent is a known, probable, or
possible human carcinogen, or ifthe agent lacks carcinogenic activity
or cannot be classified. These guidelines were used to upgrade ethyl-
ene oxide and dioxin to the "known human carcinogen" category
and to downgrade the classification ofsaccharin. These classifications
are not without controversy in that legitimate scientific debate
remains, but they demonstrate that diverse data sets can be success-
fully integrated into an overall assessment or classification.
The NTP is mandated by Congress to prepare a report that lists
agents to which a significant number ofpeople in the United States
are exposed as either known or reasonably anticipated to be human
carcinogens. The NTP, like IARC, has revised the criteria forlisting
in the report to explicitly require consideration of all relevant data
in the listing process (3). The new criteria, like IARC and EPA,
specify the use of human data, animal data, and mechanistic data,
and state that "conclusions regarding carcinogenicity in humans or
experimental animals are based on scientific judgment with consid-
eration given to all relevant information." The new criteria are now
being applied to determine listings ofnearly 25 agents or substances
in the ninth Report on Carcinogens, due to be published later this
year. Listings being considered include environmental tobacco
smoke, alcoholic beverages, crystalline silica, and benzidine-based
dyes as "known human carcinogens"; methyl tert-butyl ether
(MTBE) and diesel particulates as "reasonably anticipated to be
human carcinogens"; and the delisting from the report ofsaccharin
and ethyl acrylate. Delisting means that they are characterized as
something less than "reasonably anticipated to be a human carcino-
gen." These delistings are based on proposals that the mechanism by
which saccharin and ethyl acrylate cause cancer in animals would
not operate in people exposed to those substances. Taken together,
the efforts described above respond to the growing recognition that
multidisciplinary approaches are needed to better link scientific
knowledge to public health policy.
The SOT motion used chloroform and saccharin as examples of
situations for which mechanistic data would be used to discount
equivocal results from epidemiology studies. No one, of course, is
recommending that strong epidemiological evidence should be dis-
counted. But the SOT debate was unbalanced in that it did not
address examples for which positive mechanistic data could be used
to establish risk in the presence ofweak or nonexisting epidemiologi-
cal data. The use ofmechanistic data, including molecular epidemi-
ology studies and its interplay with evidence from traditional epi-
demiology studies, must function both to upgrade and downgrade
the classification ofsubstances. The EPA, IARC, NTP, and FDA are
explicit in their statements that mechanistic data can be used to
upgrade the results ofinconclusive epidemiology data as well, as to
downgrade. Examples forwhich such datawere used to upgrade clas-
sification of a substance should have been included as part of the
SOT debate.
Our growing understanding of the biological processes that
cause human disease are creating difficult challenges and also
unprecedented opportunities to link science to public health policy.
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We need to develop ways to better strengthen this link instead of
creating polarized views that only add to public confusion concern-
ing regulatory decisions by asking people to make choices based on
often-misleading extremes. It has been said that too much knowl-
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